logo

Lebanon

HPV Country Profile

Statistics and Data Analytics
NEW CASES OF CERVICAL CANCER IN 2018 (TOTAL)

192

cases in 2018

DEATHS FROM CERVICAL CANCER IN 2018 (TOTAL)

125

deaths in 2018

Status of National HPV Vaccination Programme

The HPV vaccine is currently not included in Lebanon's national immunization program.

Description
HPV

General Information

Human Papillomavirus

Burden of HPV infection

In Lebanon, about 2.3% of women in the general population are estimated to have HPV type 16 or 18 at a given time, which causes approximately 72.4% of invasive cervical cancers in the country. One study showed that 30.7% of women have HPV, and another showed that HPV type 16 was the most common subtype.1,4

Burden of cervical cancer

Cervical cancer, caused by HPV, is the twelfth leading cause of cancer deaths in women in Lebanon, causing at least 125 deaths annually among the population of 2.3 million Lebanese women aged 15 years and older who are at risk for the disease.1,2 Between 2012 and 2018, the number of deaths every year due to cervical cancer nearly tripled (42 in 2012 to 125 in 2018), and if decisive action is not taken at the national level, annual deaths due to the disease will increase by a factor of 1.62 by 2040, reaching 202 deaths per year.3 In Lebanon, at least 192 women are newly diagnosed with cervical cancer each year.

5.7 per 100,000 women in Lebanon contract cervical cancer annually and 3.6 per 100,000 Lebanese women die due to cervical cancer each year. Among countries in the MENA region (as defined by UNAIDS), Lebanon’s death and incidence rates due to cervical cancer are about average. For example, Somalia and Morocco have the highest incidence and mortality rates, with 24.0 and 17.2 women per 100,000 being newly diagnosed with cervical cancer annually and at least 21.9 and 12.6 women per 100,000 dying due to cervical cancer per year, respectively. Whereas Iran, Iraq and Yemen have the lowest (around 2 per 100,000 women are diagnosed per year and about 1 per 100,000 die because of cervical cancer annually).2


Cervical cancer incidence and mortality rate projections
Research and Publications
  1. Abi Jaoude, Joseph, et al. “Factors Associated with Human Papilloma Virus (HPV) Vaccine Recommendation by Physicians in Lebanon, a Cross-Sectional Study.” Vaccine, vol. 36, no. 49, Nov. 2018, pp. 7562–67, doi:10.1016/j.vaccine.2018.10.065.
  2. Choucair, J., and S. Abboud. “What Do Lebanese Women Know about Cervical Cancer and Human Papillomavirus? A Report on Awareness Levels in Urban Communities.” International Journal of Infectious Diseases, vol. 73, Aug. 2018, p. 229, doi:10.1016/j.ijid.2018.04.3935.
  3. Mhawej, R., et al. “Human Papillomavirus Prevalence and Clinicopathological Associations in Oropharyngeal Squamous Cell Carcinoma in the Lebanese Population.” The Journal of Laryngology & Otology, vol. 132, no. 7, July 2018, pp. 636–41, doi:10.1017/S0022215118001019.
  4. Hobeika, Elie, et al. “Practice and Attitudes towards Immunization among Lebanese Obstetricians and Gynecologists.” Human Vaccines & Immunotherapeutics, vol. 14, no. 6, June 2018, pp. 1501–08, doi:10.1080/21645515.2018.1440163.
  5. Seoud, Muhieddine, et al. “Awareness, Attitudes, Practices and Continuation of HPV Vaccines in Lebanon [7R].” Obstetrics & Gynecology, vol. 131, May 2018, p. 196S, doi:10.1097/01.AOG.0000533257.12358.35.
  6. Abou El-Ola, Maria J., et al. “Low Rate of Human Papillomavirus Vaccination among Schoolgirls in Lebanon: Barriers to Vaccination with a Focus on Mothers’ Knowledge about Available Vaccines.” Therapeutics and Clinical Risk Management, vol. 14, Mar. 2018, pp. 617–26, doi:10.2147/TCRM.S152737.
  7. Sharma, Monisha, et al. “Cost-Effectiveness of Increasing Cervical Cancer Screening Coverage in the Middle East: An Example from Lebanon.” Vaccine, vol. 35, no. 4, Jan. 2017, pp. 564–69, doi:10.1016/j.vaccine.2016.12.015.
  8. Maatouk, Ismaël, and Khalil Abdo. “Human Papillomavirus Prevalence in the Oral Cavity of Men Who Have Sex with Men: A Study of Its First from Beirut, Lebanon.” Sexual Health, vol. 13, no. 4, June 2016, pp. 397–99, doi:10.1071/SH16045.
  9. Homsi, Mahmoud Mohamad El, et al. “THE RISK OF DEVELOPING CERVICAL CANCER IN LEBANON.” World Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, no. 7, 2016, p. 14.
  10. Dany, Mohammed, et al. “Human Papillomavirus Vaccination: Assessing Knowledge, Attitudes, and Intentions of College Female Students in Lebanon, a Developing Country.” Vaccine, vol. 33, no. 8, Feb. 2015, pp. 1001–07, doi:10.1016/j.vaccine.2015.01.009.
  11. Karam, Walid G., et al. “Human Papillomavirus Testing as an Adjunct to Cytology Evaluation in Cervical Specimens of Selected and Consecutively Screened Lebanese Women: A Prospective Clinical Study.” Lebanese Medical Journal, vol. 53, no. 3, 2005, p. 7.
  12. Mroueh, A. M., et al. “Prevalence of Genital Human Papillomavirus among Lebanese Women.” European Journal of Gynaecological Oncology, vol. 23, no. 5, 2002, pp. 429–32.
View all publications
News
References
  1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Lebanon. Summary Report 27 July 2017. [19 October, 2018]

  2. Cancer Today. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  3. Cancer Tomorrow. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  4. El Homsi MM, Aftimos G, Tofaily Z, Hassan KH. (2016). THE RISK OF DEVELOPING CERVICAL CANCER IN LEBANON. World Journal of Pharmacy and Pharmaceutical Sciences. 5(7):18-30. ISSN 2278 – 4357.

Disclaimer
Please notify us if you know of other resources, including academic publications, news articles and information that should be added to this page by emailing: hpvmena@gmail.com.